



Pharmaids Pharmaceuticals Limited

Date: 30.07.2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Newspaper Advertisements of Recommendations of the Committee of Independent Directors in terms of Regulation 26(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“Takeover Regulations”)

Ref: Open Offer by Shankarappa Nagaraja Vinaya Babu (“Acquirer”) along with Tumkur Trade Center Private Limited (“PAC”), to acquire upto 91,69,632 Equity shares of Rs. 10/- each for cash at a price of ₹ 62.15/- (Rupees Sixty Two Point One Five only) per Equity Share aggregating upto ₹ 56,98,92,629/- (Rupees Fifty Six Crore Ninety Eight Lakh Ninety Two Thousand Six Hundred Twenty Nine only), to the Public Shareholders of Pharmaids Pharmaceuticals Limited (“Target Company”) Pursuant to and in Compliance with the Requirements of The Securities And Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (“SEBI (SAST) Regulations”) (“Offer” Or “Open Offer”).

This is with reference to the above please find the copies of Newspaper Advertisements in respect of Recommendations of the Committee of Independent Directors of the Company in terms of Regulation 26(7) of Takeover Regulations, 2011 with regard to open offer to the public shareholders of the Pharmaids Pharmaceuticals Limited (Target Company), for acquisition of Equity Shares of the Target Company.

The recommendation of Committee of Independent Directors for the Open Offer was published today, Wednesday, July 30, 2025, in the following newspapers: -

Sr. No.	Newspapers	Language	Editions
1	Financial Express	English	All Editions
2	Jansatta	Hindi	All Editions
3	Udaykala	Kannada	Bangalore Edition – Place of Registered office of Target Company is situated
4	Navshakti	Marathi	Mumbai Edition – Place of Stock Exchange at which shares of Target Company are listed

This is for your kind reference and records.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)
Encl: as above

JCK INFRASTRUCTURE DEVELOPMENT LIMITED

CIN: L70102KA1979PLC003590

No. 309, 1st Floor, Westminster Building
13, Cunningham Road, Bengaluru - 560052
Ph : 080-22203423

Email: investors@jckgroup.in Website: www.jckgroup.in

Transfer of Equity Shares of the Company to IEPF

Shareholders are hereby informed that pursuant to Section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules"), the dividend declared for the Financial Year 2017-18, which remained unclaimed for a period of seven years will be transferred/credited to the IEPF on or after 25th October 2025. The corresponding shares on which dividends remained unclaimed for seven consecutive years will also be transferred to IEPF as required under the Rules.

Individual Notices have been sent to all the concerned shareholders whose shares are liable to be transferred to IEPF as per the aforesaid Rules. Full details of such shareholders are made available on the Company's Website at https://www.jckgroup.in/investors/

The Company shall proceed to transfer the shares held by you to the IEPF Authority in compliance with the said rules, by following the due process as enumerated in the said notification which is as under:

- (1) Shareholders holding shares in physical form: by issuance of duplicate share certificate(s) and thereafter transferring the same to IEPF authority. Accordingly the original share certificate(s) which stand registered in your name will be deemed cancelled and non-negotiable.
- (2) Shareholders holding shares in demat form: Your demat account will be debited for the shares liable for transfer to the IEPF.

We request the Shareholders, in their own interest, to verify the details of shares liable to be transferred to IEPF and claim their unclaimed dividends. In the event valid claim is not received on or before 10th October 2025, the Company will proceed to transfer the liable dividend and Equity Shares in favour of IEPF Authority without any further notice.

Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares so transferred to IEPF and the details uploaded by the Company on its website shall be deemed to be adequate notice in respect of issue of Duplicate Share Certificate (s) by the Company for the purpose of transfer as aforesaid. The Shareholders may however claim the shares and dividend from IEPF Authority by making an application in Form IEPF-5 online (available on the website - www.iepf.gov.in) and sending a physical copy of the same duly signed along with other requisite documents enumerated in form IEPF-5 to the Company at its address mentioned above.

For any query or assistance, please write to our RTA or the Company at giri@integratedindia.in or investors@jckgroup.in, for prompt action.

For JCK Infrastructure Development limited

Sd/-

Krishan Kapur

Managing Director

Date: 30.07.2025

Place: Bengaluru

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

happiest minds

The Mindful IT Company

Born Digital . Born Agile

HAPPIEST MINDS TECHNOLOGIES LIMITED

CIN : L72900KA2011PLC057931
Regd. Office:#53/1-4, Hosur Main Road, Madivala (next to Madivala Police Station) Bengaluru 560 068, Karnataka, India
Website: www.happiestminds.com, Email: IR@happiestminds.com, Tel: +91 80 6196 0300

Extract of Unaudited Consolidated Financial Results for the quarter ended June 30, 2025

Particulars	₹ in lakhs			
	Quarter Ended 30-06-2025 (Unaudited)	Quarter Ended 31-03-2025 (Refer Note 2)	Quarter Ended 30-06-2024 (Unaudited)	Year Ended 31-03-2025 (Audited)
Total Income from Operations	54,990	54,457	46,382	2,06,084
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	7,687	6,254	6,841	26,762
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	7,687	5,038	6,841	25,546
Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	5,713	3,400	5,103	18,486
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	5,790	3,853	5,146	17,857
Paid-up equity share capital (₹ 2/- each)	3,003	3,001	2,991	3,001
Reserves (excluding Revaluation Reserve)	69,809	63,875	54,888	63,875
Securities Premium Account	90,619	90,582	90,389	90,582
Net worth	1,63,431	1,57,458	1,48,268	1,57,458
Paid up Debt Capital/ Outstanding Debt	1,19,207	1,16,090	1,25,405	1,16,090
Outstanding Redeemable Preference Shares	NA	NA	NA	NA
Debt Equity Ratio	0.78	0.79	0.90	0.79
Earnings Per Share (of Rs. 2/- each)				
Basic (Not annualised for quarters)	3.79	2.26	3.39	12.26
Diluted (Not annualised for quarters)	3.79	2.26	3.39	12.26
Capital Redemption Reserve	NA	NA	NA	NA
Debt Redemption Reserve	NA	NA	NA	NA
Debt Service Coverage Ratio	5.32	5.81	7.73	6.31
Interest Service Coverage Ratio	4.24	3.63	4.93	3.94

Additional information on Standalone financial results is as follows:

Particulars	Quarter Ended 30-06-2025 (Unaudited)	Quarter Ended 31-03-2025 (Refer Note 2)	Quarter Ended 30-06-2024 (Unaudited)	Year Ended 31-03-2025 (Audited)
(a) Total Income from operations	43,113	45,408	39,855	1,64,894
(b) Profit Before tax	5,503	6,193	5,982	21,327
© Profit After tax	4,058	5,776	4,384	16,856

Notes:

1. In terms of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2025 ("Consolidated Financial Results") of Happiest Minds Technologies Limited (the "Holding Company" or the "Company") and its subsidiaries (together referred to as "the Group") has been approved by the Board of Directors at their meeting held on July 29, 2025.
2. The figures of the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial year upto March 31, 2025 and the published year-to-date figure upto December 31, 2024 being the date of the end of the third quarter of the financial year. The published year-to-date results upto December 31, 2024 was subjected to a limited review by the Statutory Auditors of the Company.
3. The above is an extract of detailed format of quarterly financial results filed with the Stock Exchanges under regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. The full format of the quarterly financial results are available on the websites of the Stock exchanges where shares of the Company are listed i.e. www.bseindia.com and www.nseindia.com and also on the website of the Company i.e. www.happiestminds.com. The same can be accessed by scanning the QR code provided below.



For Happiest Minds Technologies Limited

Sd/-
Managing Director

Place: Bengaluru, India
Date: July 29, 2025

MUTUALFUNDS

Sahi Hai



Haq, ek behtar zindagi ka.

Notice For Declaration Of Income Distribution Cum Capital Withdrawal

UTI Conservative Hybrid Fund (Erstwhile UTI Regular Savings Fund)

Name of the Plan	Quantum of IDCW (Gross Distributable Amt.)*		Record Date	Face Value (per unit)	NAV as on July 28, 2025 (per unit)
	%	₹ per unit			₹
UTI Conservative Hybrid Fund - Regular Plan - Monthly Income Distribution cum capital Withdrawal option (IDCW)	0.80%	0.0800	Friday August 01, 2025	₹10.00	17.5887
UTI Conservative Hybrid Fund - Direct Plan - Monthly Income Distribution cum capital Withdrawal option (IDCW)					19.7978

*Distribution of above IDCW is subject to the availability of distributable surplus as on record date. Income distribution cum capital withdrawal payment to the investor will be lower to the extent of statutory levy (if applicable). Income distribution will be made, net of tax deducted at source as applicable.

Pursuant to payment of IDCW, the NAV of the income distribution cum capital withdrawal options of the scheme would fall to the extent of payout and statutory levy (if applicable).

Such of the unitholders under the income distribution cum capital withdrawal options whose names appear in the register of unitholders as at the close of business hours on the record date fixed for each income distribution cum capital withdrawal shall be entitled to receive the income distribution cum capital withdrawal so distributed. The reinvestment, if any, shall be treated as constructive payment of IDCW to the unitholders as also constructive receipt of payment of the amount by the unitholders. No load will be charged on units allotted on reinvestment of IDCW.

Mumbai

July 29, 2025

Toll Free No.: 1800 266 1230

www.utmfm.com

REGISTERED OFFICE: UTI Tower, 'Gn' Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400051. Phone: 022 - 66786666. UTI Asset Management Company Ltd. (Investment Manager for UTI Mutual Fund) E-mail: invest@uti.co.in, (CIN-L65991MH2002PLC137867).

For more information, please contact the nearest UTI Financial Centre or your AMFI/ NISM certified Mutual Fund Distributor, for a copy of Statement of Additional Information, Scheme Information Document and Key Information Memorandum cum Application Form.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

PHARMAIDS PHARMACEUTICALS LIMITED

Registered Office: Unit 201, 2nd Floor, Brigade Rubik, 20/14, HMT Factory Main Road, Peenya Plantation, Bengaluru, Karnataka, India - 560013. | Corporate Identification Number: L52520KA1989PLC173979
Tel: +91-9611551732 / 080-49784319 | Email: compliance@pharmaids.com | Website: www.pharmaids.com

Recommendations of the Committee of Independent Directors (the "IDC") of Pharmaids Pharmaceuticals Limited (the "Target Company") under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (the "SEBI (SAST) Regulations, 2011") in relation to the open offer to the public shareholders of the Target Company made by Shankarappa Nagaraja Vinaya Babu ("Acquirer"), along with Tumkur Trade Center Private Limited ("PAC").

Sr. No.	Topic	Particular
1.	Date	July 28, 2025
2.	Name of the Target Company	Pharmaids Pharmaceuticals Limited
3.	Details of the Offer pertaining to Target Company	The Open Offer is being made by the Acquirer along with PAC in terms of Regulations 3(1) and 4 of the SEBI (SAST) Regulations, 2011 for acquisition of up to 91,69,632 (Ninety One Lakh Sixty Nine Thousand Six Hundred Thirty Two) fully paid-up equity shares of face value of ₹10/- each (the "Equity Shares"), representing 26% (Twenty Six Percent) of the total Voting Share Capital of the Target Company on a fully diluted basis from the eligible shareholders of the Target Company for cash at a price of ₹ 62.15/- (Rupees Sixty Two Point One Five Only) per equity share ("Open Offer").
4.	Name of the Acquirer and PAC with the Acquirer	Acquirer: Shankarappa Nagaraja Vinaya Babu PAC: Tumkur Trade Center Private Limited CIN: U45403KA2018PTC113380
5.	Name of the Manager to the Offer	Saffron Capital Advisors Private Limited 605, Sixth Floor, Centre Point, Andheri-Kurla Road, J. B. Nagar, Andheri (East), Mumbai-400 059 Maharashtra, India. Tel. No.: +91 22 49730394 Email Id: openoffers@saffronadvisor.com Website: www.saffronadvisor.com Investor Grievance Id: investorgrievance@saffronadvisor.com SEBI Registration Number: INM000011211 Contact Person: Satej Darde / Sachin Prajapati
6.	Members of the Committee of Independent Directors ("IDC Members" or "Members of the IDC")	i. Mr. Pattamadai Natarajasarma Vijay (DIN: 00049992) – Chairperson and Member ii. Mr. Methuku Nagesh (DIN: 01634324) - Member iii. Mr. Mopperthy Sudheer (DIN: 00404917) - Member
7.	IDC Member's relationship with the Target Company (Director, Equity shares owned, any other contract/ relationship), if any	i. All IDC Members are Independent and Non -Executive Directors on the Board of the Target Company. ii. Further, the members of IDC confirm that they do not hold any Equity Shares or other securities in the Target Company. iii. Other than their positions as Directors of the Target Company, there are no other contracts or relationships with the Target Company.
8.	Trading in the Equity shares/ other securities of the Target Company by IDC Members	None of the members of the IDC has traded in Equity Shares/ other securities of the Target Company during the: i. 12 (twelve) months period prior to the date of the Public Announcement ("PA") dated Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.
9.	IDC Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any.	None of the members of the IDC have any contractual or any other relationship with the Acquirer along with PAC.
10.	Trading in the Equity shares/ other securities of the Acquirer by IDC Members	Not Applicable as the Acquirer is an individual. Further, none of the IDC members has traded in Equity Shares of PAC during the: i. 12 (twelve) months period prior to the date of the PA i.e., Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.
11.	Recommendation on the Open offer, as to whether the offer, is or is not, fair and reasonable	Based on the review, a) The IDC Members are of the view that the Offer Price of ₹62.15/- (Rupees Sixty Two Point One Five only) per Equity Share is in line with the parameters prescribed by the SEBI (SAST) Regulations, 2011; b) IDC Members believe that the Offer is in line with the SEBI (SAST) Regulations, 2011 and the same is fair and reasonable. However, IDC members would like to draw the attention of the Shareholders that, the Equity Shares of the Target Company are trading on BSE at a price that is higher than the Offer Price; and c) It is advised to the shareholders to independently evaluate the open offer vis-à-vis current share price and take an informed decision before participating in the Offer.
12.	Summary of reasons for recommendation	1. The IDC Members have reviewed: a) Public Announcement ("PA") dated December 27, 2024; b) Detailed Public Statement ("DPS") dated January 02, 2025 and was published on January 03, 2025; c) Draft Letter of Offer ("DLOF") dated January 10, 2025; d) Letter of Offer ("LOF") dated July 23, 2025; 2. The IDC members also noted that: a) The Equity Shares of the Target Company are frequently traded in terms of Regulations 2(1)(j) of the SEBI (SAST) Regulations, 2011. b) The Offer Price is in accordance with Regulations 8(1) and 8(2) of the SEBI (SAST) Regulations, 2011. c) The Offer Price of ₹ 62.15/- per Equity Share is higher than (i) negotiated price under the Share Purchase Agreement executed on December 27, 2024, i.e. ₹35/- per Equity Share and higher than (ii) the volume-weighted average market price of shares for a period of sixty trading days immediately preceding the date of the PA as traded on the BSE, being only stock exchange where the equity shares of the Target Company are listed, i.e. ₹62.13/- per Equity Share. Based on the above, the IDC Members are of the view that the Offer Price of ₹ 62.15/- per equity share is in line with the parameters prescribed by SEBI (SAST) Regulations, 2011.
13.	Disclosure of voting pattern	These recommendations were unanimously approved by the Members of the IDC.
14.	Details of Independent Advisors, if any.	None
15.	Any other matter to be highlighted	None

Terms not defined herein carry the meaning ascribed to them in the Letter of Offer dated July 23, 2025.

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations, 2011.

For and on behalf of the Committee of Independent Directors of Pharmaids Pharmaceuticals Limited

Sd/-

Pattamadai Natarajasarma Vijay

Chairperson of IDC

DIN: 00049992

Place: Philadelphia, Pennsylvania, USA

Date: July 28, 2025



IGI

www.igi.org



INTERNATIONAL GEMMOLOGICAL INSTITUTE (INDIA) LIMITED

CIN: L46591MH1999PLC118476

Registered Office: 702, 7th Floor, The Capital, Bandra Kurla Complex, Bandra East, Mumbai - 400051, Maharashtra, India.

Email: investor.relations@igi.org | Website:www.igi.org

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED JUNE 30, 2025

(Amounts in INR millions, unless otherwise stated)

Particulars	Standalone					
	Quarter ended June 30, 2025	Corresponding quarter ended March 31, 2025	Quarter ended June 30, 2024	Six months ended June 30, 2025	Six months ended June 30, 2024	Year ended December 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income from operations	2,486.41	2,443.87	2,089.22	4,930.28	4,243.35	8,165.23
Net Profit for the period/ year (before tax)	1,807.88	1,876.36	1,314.73	3,684.24	2,996.96	5,868.27
Net Profit for the period/ year (after tax)	1,374.80	1,391.43	961.21	2,766.23	2,216.17	4,392.49
Total Comprehensive income for the period/ year (Comprising Profit/Loss) for the period (after tax) and Other comprehensive income (after tax)	1,371.46	1,388.03	961.21	2,759.49	2,203.03	4,378.89
Paid up Equity Share Capital						864.32
(Face value of ₹ 2 per share)						
Reserves excluding revaluation reserve as at Balance Sheet date						21,010.56
Earning per share:						
1. Basic (in ₹) (not annualised)	3.18	3.22	2.42	6.40	5.59	11.04
2. Diluted (in ₹) (not annualised)	3.06	3.09	2.42	6.15	5.59	10.57

(Amounts in INR millions, unless otherwise stated)

Particulars	Consolidate					
	Quarter ended June 30, 2025	Corresponding quarter ended March 31, 2025	Quarter ended June 30, 2024	Six months ended June 30, 2025	Six months ended June 30, 2024	Year ended December 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income from operations	3,146.13	3,132.15	2,624.92	6,278.28	5,529.23	10,884.92
Net Profit for the period/ year (before tax)	1,749.69	1,914.73	1,139.96	3,664.42	2,850.85	5,853.20
Net Profit for the period/ year (after tax)	1,265.32	1,407.26	778.40	2,672.58	2,039.16	4,272.90
Total Comprehensive income for the period/ year (Comprising Profit/Loss) for the period (after tax) and Other comprehensive income (after tax)	1,341.76	1,451.88	716.32	2,793.64	1,963.63	4,336.18
Paid up Equity Share Capital						864.32
(Face value of ₹ 2 per share)						
Reserves excluding revaluation reserve as at Balance Sheet date						9,763.17
Earning per share:						
1. Basic (in ₹) (not annualised)	2.92	3.26	1.96	6.18	5.14	10.74
2. Diluted (in ₹) (not annualised)	2.81	3.13	1.96	5.94	5.14	10.28

Notes:

1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Reports) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on Stock Exchange websites.
2. The above financial results for the quarter ended June 30, 2025 have been duly reviewed by Audit Committee and were taken on record by the Board of Directors at its meeting held on July 29, 2025.
3. Figures for the previous periods have been regrouped/rearranged wherever necessary to confirm to current period's classification.



July 29, 2025
Mumbai

By order of the Board
Sd/-

Tehmasp Printer
(Managing Director & CEO)

PHARMAIDS PHARMACEUTICALS LIMITED		
Registered Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14, HMT Factory Main Road, Peenya Plantation, Bengaluru, Karnataka, India - 560013 Corporate Identification Number: L52520KA1989PLC173979 Tel: +91-9611551732 / 080-49784319 Email: compliance@pharmaids.com Website: www.pharmaids.com		
Recommendations of the Committee of Independent Directors (the "IDC") of Pharmaida Pharmaceuticals Limited (the "Target Company") under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (the "SEBI (SAST) Regulations, 2011") in relation to the open offer to the public shareholders of the Target Company made by Shankarappa Nagaraja Vinaya Babu ("Acquirer"), along with Tumkur Trade Center Private Limited ("PAC").		
Sr. No.	Topic	Particular
1.	Date	July 28, 2025
2.	Name of the Target Company	Pharmaida Pharmaceuticals Limited
3.	Details of the Offer pertaining to Target Company	<p>The Open Offer is being made by the Acquirer along with PAC in terms of Regulations 3(1) and 4 of the SEBI (SAST) Regulations, 2011 for acquisition of up to 91,69,632 (Ninety One Lakh Sixty Nine Thousand Six Hundred Thirty Two) fully paid-up equity shares of face value of ₹10/- each (the "Equity Shares"), representing 26% (Twenty Six Percent) of the total Voting Share Capital of the Target Company on a fully diluted basis from the eligible shareholders of the Target Company for cash at a price of ₹ 62.15/- (Rupees Sixty Two Point One Five Only) per equity share ("Open Offer").</p> <p>Acquirer: Shankarappa Nagaraja Vinaya Babu PAC: Tumkur Trade Center Private Limited CIN: U45403KA2018PTC113380 Saffron Capital Advisors Private Limited 605, Sixth Floor, Centre Point, Andheri-Kurla Road, J. B. Nagar, Andheri (East), Mumbai-400 059 Maharashtra, India. Tel. No.: +91 22 49730394 Email Id: openoffers@saffronadvisior.com Website: www.saffronadvisior.com Investor Grievance Id: investor grievance@saffronadvisior.com SEBI Registration Number: INM000011211 Contact Person: Satej Darde / Sachin Prajapati</p>
4.	Name of the Acquirer and PAC with the Acquirer	
5.	Name of the Manager to the Offer	
6.	Members of the Committee of Independent Directors ("IDC Members" or "Members of the IDC")	<p>i. Mr. Pattamadai Natarajasarma Vijay (DIN: 00049992) – Chairperson and Member ii. Mr. Methuku Nagesh (DIN: 01634324) - Member iii. Mr. Mopperthy Sudheer (DIN: 00404917) - Member</p>
7.	IDC Member's relationship with the Target Company (Director, Equity shares owned, any other contract / relationship), if any	<p>i. All IDC Members are Independent and Non-Executive Directors on the Board of the Target Company. ii. Further, the members of IDC confirm that they do not hold any Equity Shares or other securities in the Target Company. iii. Other than their positions as Directors of the Target Company, there are no other contracts or relationships with the Target Company.</p>
8.	Trading in the Equity shares/ other securities of the Target Company by IDC Members	<p>None of the members of the IDC has traded in Equity Shares/ other securities of the Target Company during the:</p> <p>i. 12 (twelve) months period prior to the date of the Public Announcement ("PA") dated Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.</p>
9.	IDC Member's relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any.	<p>None of the members of the IDC have any contractual or any other relationship with the Acquirer along with PAC.</p>
10.	Trading in the Equity shares/ other securities of the Acquirer by IDC Members	<p>Not Applicable as the Acquirer is an individual.</p> <p>Further, none of the IDC members has traded in Equity Shares of PAC during the:</p> <p>i. 12 (twelve) months period prior to the date of the PA i.e., Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.</p>
11.	Recommendation on the Open offer, as to whether the offer, is or is not, fair and reasonable	<p>Based on the review,</p> <p>a) The IDC Members are of the view that the Offer Price of ₹62.15/- (Rupees Sixty Two Point One Five only) per Equity Share is in line with the parameters prescribed by the SEBI (SAST) Regulations, 2011;</p> <p>b) IDC Members believe that the Offer is in line with the SEBI (SAST) Regulations, 2011 and the same is fair and reasonable. However, IDC members would like to draw the attention of the Shareholders that, the Equity Shares of the Target Company are trading on BSE at a price that is higher than the Offer Price; and</p> <p>c) It is advised to the shareholders to independently evaluate the open offer vis-à-vis current share price and take an informed decision before participating in the Offer.</p>
12.	Summary of reasons for recommendation	<p>1. The IDC Members have reviewed:</p> <p>a) Public Announcement ("PA") dated December 27, 2024;</p> <p>b) Detailed Public Statement ("DPS") dated January 02, 2025 and was published on January 03, 2025;</p> <p>c) Draft Letter of Offer ("DLOF") dated January 10, 2025;</p> <p>d) Letter of Offer ("LOF") dated July 23, 2025;</p> <p>2. The IDC members also noted that:</p> <p>a) The Equity Shares of the Target Company are frequently traded in terms of Regulations 2(1)(i) of the SEBI (SAST) Regulations, 2011.</p> <p>b) The Offer Price is in accordance with Regulations 8(1) and 8(2) of the SEBI (SAST) Regulations, 2011.</p> <p>c) The Offer Price of ₹ 62.15/- per Equity Share is higher than (i) negotiated price under the Share Purchase Agreement executed on December 27, 2024, i.e. ₹35/- per Equity Share and higher than (ii) the volume-weighted average market price of shares for a period of sixty trading days immediately preceding the date of the PA as traded on the BSE, being only stock exchange where the equity shares of the Target Company are listed, i.e. ₹62.13/- per Equity Share.</p> <p>Based on the above, the IDC Members are of the view that the Offer Price of ₹ 62.15/- per equity share is in line with the parameters prescribed by SEBI (SAST) Regulations, 2011.</p>
13.	Disclosure of voting pattern	These recommendations were unanimously approved by the Members of the IDC.
14.	Details of Independent Advisors, if any.	None
15.	Any other matter to be highlighted	None
Terms not defined herein carry the meaning ascribed to them in the Letter of Offer dated July 23, 2025. To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations, 2011.		
For and on behalf of the Committee of Independent Directors of Pharmaida Pharmaceuticals Limited Sd/- Pattamadai Natarajasarma Vijay Chairperson of IDC DIN: 00049992		
Place: Philadelphia, Pennsylvania, USA Date: July 28, 2025		

ऑफिस-होती अभियंता की अभिव्यक्ति हेतु आमंत्रण	
नृतिट प्रॉपर्टी प्राइवेट लिमिटेड	
रियल एस्टेट क्षेत्र 1, कस्तूरबा गौरी मार्ग, उत्तरी दिल्ली, नई दिल्ली, भारत, 110001 में कार्यरत, (रियास और सोहन अग्रवाल) (विशेषकर महिलाओं के लिए निवेश समर्थक प्रयोग) निर्माणप्रमुख, 20116 के निर्देशन 300 के उप-निर्देश[1] के अधीन।	
प्रासंगिक विवरण	
1. पैन/टीआईएन/एसएमसी संख्या के साथ क्षेत्रीय रेकर्डर का नाम	नृतिट प्रॉपर्टी प्राइवेट लिमिटेड CIN: U45201DL2004PTC130198 PAN: AABCE4526H
2. पीओबी कार्यालय का पता	1. कस्तूरबा गौरी मार्ग, उत्तरी दिल्ली, नई दिल्ली, दिल्ली, भारत, 110001
3. वेबसाइट का यूआरएल	उपलब्ध नहीं
4. उस स्थान का विवरण जहां अप्रत्यक्ष निर्माणों का बहुमूल स्थित है	1. कस्तूरबा गौरी मार्ग, उत्तरी दिल्ली, नई दिल्ली, दिल्ली, भारत, 110001
5. कोर्पोरेट रेकर्डर के मुख्य उपाध्यक्ष/सोकाओं की स्थापित क्षमता	उपलब्ध नहीं
6. पिछले निर्माण एवं मैं बेचे गए मुख्य उपाध्यक्ष/सोकाओं की मात्रा और मूल्य	उपलब्ध नहीं
7. रजिस्ट्रार/वी/रजिस्टर की संख्या	उपलब्ध नहीं
8. यी सीके के अनुरूप उपलब्ध निर्माण विवरणों (अनुसूचित) के साथ केन्द्रों की सूची निर्माणों की यात्रा की परतों की हेतु प्राप्तियों/निर्माणों सहित अधिक विस्तृत निर्माणों/यूआरएल पर उपलब्ध है।	https://drive.google.com/drive/folders/ 1NwYnBgBjWg_wr6BgRzFvWONi1UVCJ-a?
9. सॉफ्टवेयर की बहाल 25(2)(घ) के तहत सम्मान आने वाला/समाप्त होने के लिए प्रस्ताव प्राप्त उपलब्ध है।	https://drive.google.com/drive/folders/ 1NwYnBgBjWg_wr6BgRzFvWONi1UVCJ-a?
10. रजिस्टर की अभिव्यक्ति प्राप्त करने की ऑनलाइन तिथि	14.08.2025 (30.07.2025 से 15 दिन)
11. निर्माणों/संरचनाओं आवेदनको की ऑनलाइन जारी करने की तिथि	19.08.2025 (14.08.2025 से 5 दिन)
12. ऑनलाइन सूची पर आवेदन प्राप्त प्रस्तुत करने की ऑनलाइन तिथि	24.08.2025 (19.08.2025 से 5 दिन)
13. निर्माणों/समाधान आवेदनों की ऑनलाइन सूची जारी करने की तिथि	27.08.2025 (24.08.2025 से 3 दिन)
14. निर्माणों/समाधान आवेदनों को सुचना प्राप्त, मुद्रांकन मैट्रिक्स और समाधान योजनाओं के लिए अनुस्यूत जारी करने की तिथि	28.08.2025 (27.08.2025 से 1 दिन)
15. निर्माणों/समाधान प्रस्तुत करने की ऑनलाइन तिथि	27.09.2025 (28.08.2025 से 30 दिन)
16. रजिस्टर की अभिव्यक्ति प्रस्तुत करने के लिए रिमोन आवेदी प्रक्रिया	cirp.nurtit@resurgentrpl.com
सुधीर शर्मा - अधिकृत हस्ताक्षरकर्ता	
रिटर्नैड टेलीकम्यूनिकेशन प्रोफेशनल एसोसिएट मेसर्स नृतिट प्रॉपर्टी प्राइवेट लिमिटेड के सौजन्यपूर्ण रूप से संबंधित प्रोफेशनल आईसीडीआई पंजीकरण: IBB/IPE-0084/1PA-3/202233, 500118	
एप्रैच 31 दिसंबर 2025 तक नाम	
पता: 905, 9वीं मील, ठौर-ठीक, मुनिटेड बिजनेस जेन, सेक्टर 50, गुडगांव, हरियाणा 122018	
ईमेल: cirp.nurtit@resurgentrpl.com	
दिनांक: 30.07.2025	

 NACL Industries Limited CIN: L24219TG1986PLC016607	
Registered Office: Plot No.12-A, "C" Block, Lakshmi Towers, No.8-2-248/1/7/7/8, Nagarjuna Hills, Panjagutta, Hyderabad-500082, Telangana State, India Phone: 040-24405100; e-mail: investors@naclind.com; Website: www.naclind.com	
Recommendations of the Committee of Independent Directors ("IDC") constituted by the Board of Directors of M/s. NACL Industries Limited ("Target Company") on the Open Offer made by M/s. Coromandel International Limited ("Acquirer") to the public shareholders of the Target Company under Regulation 26(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI (SAST) Regulations")	
1 Date :	July 28, 2025
2 Name of the Target Company (TC) :	NACL Industries Limited
3 Details of the Offer pertaining to TC :	<p>Open Offer for acquisition of up to 52,462,320 fully paid-up equity shares of face value of ₹1 each ("Equity Shares"), representing 26.00% (twenty six percent) of the Voting Share Capital of Target Company from the public shareholders of the Target Company pursuant to and in compliance with the requirements of the SEBI (SAST) Regulations.</p> <p>Offer Price: Rs.76.70/-</p> <p>Mode of Payment: Cash</p> <p>Public Announcement dated March 12, 2025 (the "PA"), Detailed Public Statement dated March 19, 2025 which was published on March 20, 2025 (the "DPS"), Draft Letter of Offer dated March 27, 2025 (the "DLoF") and Corrigendum to Public Announcement, Detailed Public Statement and Draft Letter of Offer dated March 28, 2025 which was published on March 29, 2025 (the "Corrigendum") have been issued by JM Financial Limited ("Manager to Open Offer"), on behalf of the Acquirer.</p>
4 Name(s) of the Acquirer and PAC with the Acquirer :	<p>M/s. Coromandel International Limited ("Acquirer").</p> <p>As stated by the Acquirer in the Draft Letter of Offer, there are no persons acting in concert with the Acquirer in relation to the Open Offer.</p>
5 Name of the Manager to the offer :	<p>JM Financial Limited</p> <p>Address: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai – 400 025, India.</p> <p>Tel: +91 22 6630 3030</p> <p>Fax: +91 22 6630 3330</p> <p>E-mail: naclopenoffer@jmfml.com</p> <p>Website: www.jmfml.com</p> <p>Contact person: Ms. Prachee Dhuri</p> <p>SEBI registration no.: INM000010361</p>
6 Members of the Committee of Independent Directors :	<p>a) Mr. Sudhakar Kudva (DIN 02410695) – Chairman</p> <p>b) Mr. Ram Krishna Mudholkar (DIN 00012850) – Member</p> <p>c) Mr. Santanu Mukherjee (DIN 07716452)– Member</p> <p>d) Mr. N Sambasiva Rao (DIN 06400663) – Member</p> <p>e) Ms. Veni Mocherla (DIN 08082163) – Member</p> <p>f) Dr. M. Lakshmi Kantham (DIN 07831607)– Member</p>
7 IDC Member's relationship with the TC (Director, Equity shares owned, any other contract / relationship), if any :	<p>a) All the members of the IDC are Non-Executive Independent Directors on the Board of Directors of the Target Company.</p> <p>b) None of the members of IDC hold any equity shares in the Target Company.</p> <p>c) Except as mentioned below, none of the members of the IDC have entered into any contract or have any relationship with the Target Company:</p> <p>i. Mr. Santanu Mukherjee is the Chairman of the Audit committee, Nomination and Remuneration Committee and Banking Committee.</p> <p>ii. Mr. Sudhakar Kudva is the Chairman of Stakeholders Relationship Committee, CSR Committee and Risk Management Committee. He is also a member of Nomination and Remuneration Committee, Audit Committee and Banking Committee.</p> <p>iii. Mr. N Sambasiva Rao is the member of Audit Committee.</p> <p>iv. Ms. Veni Mocherla is the member of CSR Committee.</p>
8 Trading in the Equity shares/other securities of the Target Company by IDC Members :	<p>None of the members of the IDC have traded in any of the equity shares/ securities of the Target Company (i)during the 12-month period preceding the date of the PA; and (ii) during the period from the date of the PA and till the date of this recommendation.</p>
9 IDC Member's relationship with the Acquirer (Director, Equity shares owned, any other contract / relationship), if any :	<p>None of the members of IDC:</p> <p>a) are Directors on the Board of the Acquirer;</p> <p>b) holds any equity shares or other securities of the Acquirer; and</p> <p>c) have any contracts/ relationship with the Acquirer.</p>
10 Trading in the Equity shares/other securities of the Acquirer by IDC Members :	<p>None of the members of the IDC have traded in any of the equity shares/ securities of the Acquirer during the:</p> <p>a) 12 months period preceding the date of the PA; and</p> <p>b) period from the date of the PA and till the date of this recommendation.</p>
11 Recommendation on the Open offer, as to whether the offer is fair and reasonable :	<p>The IDC has perused the PA, DPS, DLoF, and the Corrigendum issued by JM Financial Limited on behalf of the Acquirer, the members of the IDC believe that the offer is fair and reasonable and in line with the SEBI (SAST) Regulations.</p> <p>However, the public shareholders of the Target Company are advised to independently evaluate the Open Offer and make informed decision about whether or not to tender their shares in the Open Offer.</p> <p>Further, members of the IDC confirm that the Target Company has not received any complaint from the public shareholders regarding the Open Offer process, valuation price or valuation method.</p>
12 Summary of reasons for recommendation (IDC may also invite attention to any other place, e.g. company's website, where its detailed recommendations along with written advice of the independent adviser, if any can be seen by the shareholder) :	<p>The IDC has reviewed the PA, DPS, the DLoF and the Corrigendum issued / submitted by JM Financial Limited for and on behalf of the Acquirer and believe that the Offer Price of Rs. 76.70 per fully paid up Equity Share ("Offer Price") offered by the Acquirer (being the highest price prescribed) is in line with the SEBI (SAST) Regulations and prima facie appears to be fair and reasonable based on an independent valuation certificate dated July 28, 2025 issued by M/s. M.H.B & Associates, Chartered Accountants FRN: 140966W (Ms. Mamta Bhatia, Designated Partner, membership number: 114050). The Offer Price is higher than the volume-weighted average market price of the Target Company's equity shares for a period of 60 trading days immediately preceding the date of the PA as traded on stock exchange with maximum volume of trading [National Stock Exchange of India Limited (NSE)] i.e. Rs. 65.30 per Equity Share.</p> <p>Further, the members of the IDC draw attention to the closing market price of the Equity Shares of the Target Company on NSE as on July 28, 2025 being Rs. 279.29 per Equity Share, which is higher than the Offer Price. Accordingly, the Public Shareholders of the Target Company are advised to independently evaluate the Offer and make informed decisions on whether or not to offer their shares in the Open Offer.</p> <p>This statement of recommendation will be available on the website of the Company at www.naclind.com</p>
13 Disclosure of the voting pattern of the IDC Meeting :	The recommendations were unanimously approved by the members of the IDC present in the Meeting held on July 28, 2025.
14 Details of Independent Advisors, if any :	M/s. M.H.B & Associates, Chartered Accountants, Mumbai.
15 Any other matter(s) to be highlighted :	None

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the TC under the Takeover Code."

For and on behalf of the Committee of Independent Directors of NACL Industries Limited

Sd/-
Sudhakar Kudva
Chairman of the Committee of Independent Directors
(DIN 02410695)

Date : July 28, 2025
Place : Hyderabad



LIC MUTUAL FUND

LIC Mutual Fund Asset Management Limited

(Investment Managers to LIC Mutual Fund)

CIN No: U67190MH1994PLC077858

Registered Office: Industrial Assurance Bldg, 4th Floor, Opp. Churchgate Station, Mumbai - 400 020

Tel.No.: 022-66016000 Toll Free No.: 1800 258 5678 Fax No.: 022-66016191

Email: service_licmf@kfinitech.com • Website: www.licmf.com

NOTICE No. 29 of 2025-2026

Hosting of the Annual Report of the Schemes of LIC Mutual Fund for the Financial Year ended 31st March 2025

Notice is hereby given that in terms of Regulation 56 of SEBI (Mutual Funds) Regulations, 1996 and circulars issued by SEBI from time to time, the Annual Report of all the Schemes of LIC Mutual Fund for the financial year ended 31st March 2025 has been hosted on the website of LIC Mutual Fund viz. www.licmf.com and on the website of Association of Mutual Funds in India (AMFI) viz. www.amfiindia.com.

Unitholders can view or download the Annual Report from the website of LIC Mutual Fund or AMFI's website or submit a request for a physical or electronic copy of the Annual Report by any of the following modes:

- 1) Calling on toll free number: 1800-258-5678 from 9.00 a.m. to 6.30 p.m., Monday to Saturday; or
- 2) Sending an email to service_licmf@kfinitech.com from registered email id; or
- 3) Sending a duly signed written request to any of the Investor Service Centers of LIC Mutual Fund.

Investors/Unit holders are requested to take note of the same.

Date : 29th July, 2025

Place: Mumbai

For LIC MUTUAL FUND ASSET MANAGEMENT LIMITED

Sd/-

Authorized Signatory


As part of Go-Green initiative, investors are encouraged to register/update their email ID and Mobile Number with us to support paper-less communication.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

<p>NACL Industries Limited</p> <p>CIN: L24219TG1986PLC016607</p> <p>Investors, No.8-2-248/1/7/78, Nagarajuna Hills, Panjagutta, Hyderabad-500082, Telangana State, India Tel: 080-26630300; e-mail: investors@naciind.com; Website: www.naciind.com</p> <p>constituted by the Board of Directors of M/s. NACL Industries Limited ("Target Company") on the Open Offer made by the holders of the Target Company under Regulation 26(7) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers Regulations, 1992)</p>
<p>2025</p> <p>NACL Industries Limited</p> <p>Offer for acquisition of up to 52,462,320 fully paid-up equity shares of face value of ₹1 each ("Equity Shares"), representing (twenty six percent) of the Voting Share Capital of Target Company from the public shareholders of the Target Company and in compliance with the requirements of the SEBI (SAST) Regulations.</p> <p>Price: Rs.76.70/-</p> <p>Payment: Cash</p> <p>Announcement dated March 12, 2025 (the "PA"), Detailed Public Statement dated March 19, 2025 which was published on 04.03.2025 (the "DPS"), Draft Letter of Offer dated March 27, 2025 (the "DLoF") and Corrigendum to Public Announcement, Draft Public Statement and Draft Letter of Offer dated March 28, 2025 which was published on March 29, 2025 (the "Corrigendum") are issued by JM Financial Limited ("Manager to Open Offer"), on behalf of the Acquirer.</p> <p>from Jomandel International Limited ("Acquirer").</p> <p>by the Acquirer in the Draft Letter of Offer, there are no persons acting in concert with the Acquirer in relation to the Open Offer.</p> <p>Acquirer: Jomandel International Limited</p> <p>7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai – 400 025, India.</p> <p>22 6630 3030</p> <p>22 6630 3330</p> <p>naclopenoffer@jmfml.com</p> <p>www.jmfml.com</p> <p>person: Ms. Prachee Dhuri</p> <p>Registration no.: INM000010361</p> <p>Sudhakar Kudva (DIN 02410695) – Chairman</p> <p>Ram Krishna Mudholkar (DIN 00012850) – Member</p> <p>Santanu Mukherjee (DIN 07716452) – Member</p> <p>N Sambasiva Rao (DIN 06400663) – Member</p> <p>Venii Mocherla (DIN 08082163) – Member</p> <p>M. Lakshmi Kantham (DIN 07831607) – Member</p>
<p>the members of the IDC are Non-Executive Independent Directors on the Board of Directors of the Target Company. One of the members of IDC hold any equity shares in the Target Company.</p> <p>cept as mentioned below, none of the members of the IDC have entered into any contract or have any relationship with the Target Company:</p> <p>Santanu Mukherjee is the Chairman of the Audit committee, Nomination and Remuneration Committee and Banking Committee.</p> <p>Sudhakar Kudva is the Chairman of Stakeholders Relationship Committee, CSR Committee and Risk Management Committee. He is also a member of Nomination and Remuneration Committee, Audit Committee and Banking Committee.</p> <p>N Sambasiva Rao is the member of Audit Committee.</p> <p>Venii Mocherla is the member of CSR Committee.</p> <p>members of the IDC have traded in any of the equity shares/ securities of the Target Company (i)during the 12-month period preceding the date of the PA; and (ii) during the period from the date of the PA and till the date of this recommendation.</p> <p>the members of IDC:</p> <p>Directors on the Board of the Acquirer;</p> <p>owns any equity shares or other securities of the Acquirer; and</p> <p>has any contracts/ relationship with the Acquirer.</p> <p>the members of the IDC have traded in any of the equity shares/ securities of the Acquirer during the 12-months period preceding the date of the PA; and</p> <p>period from the date of the PA and till the date of this recommendation.</p> <p>has perused the PA, DPS, DLoF, and the Corrigendum issued by JM Financial Limited on behalf of the Acquirer, the members of the IDC believe that the offer is fair and reasonable and in line with the SEBI (SAST) Regulations.</p> <p>the public shareholders of the Target Company are advised to independently evaluate the Open Offer and make informed decisions about whether or not to tender their shares in the Open Offer.</p> <p>members of the IDC confirm that the Target Company has not received any complaint from the public shareholders regarding the Open Offer process, valuation price or valuation method.</p> <p>has reviewed the PA, DPS, the DLoF and the Corrigendum issued / submitted by JM Financial Limited for and on behalf of the Acquirer and believe that the Offer Price of Rs. 76.70 per fully paid up Equity Share ("Offer Price") offered by the Acquirer (at the highest price prescribed) is in line with the SEBI (SAST) Regulations and prima facie appears to be fair and reasonable in view of an independent valuation certificate dated July 28, 2025 issued by M/s. M.H.B & Associates, Chartered Accountants (Firm No. 09966W (Ms. Mamta Bhatia, Designated Partner, membership number: 114050). The Offer Price is higher than the volume-weighted average market price of the Target Company's equity shares for a period of 60 trading days immediately preceding the date of the PA as traded on stock exchange with maximum volume of trading [National Stock Exchange of India Limited (NSE)] i.e. ₹76.70 per Equity Share.</p> <p>the members of the IDC draw attention to the closing market price of the Equity Shares of the Target Company on NSE as of July 28, 2025 being Rs. 279.29 per Equity Share, which is higher than the Offer Price. Accordingly, the Public Shareholders of the Target Company are advised to independently evaluate the Offer and make informed decisions on whether or not to offer their shares in the Open Offer.</p> <p>Statement of recommendation will be available on the website of the Company at www.naciind.com</p> <p>Recommendations were unanimously approved by the members of the IDC present in the Meeting held on July 28, 2025.</p> <p>H.B & Associates, Chartered Accountants, Mumbai.</p>
<p>Information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether or not required to be disclosed by the TC under the Takeover Code."</p> <p>Committee of Independent Directors of NACL Industries Limited</p> <p>Sd/-</p> <p>Sudhakar Kudva</p> <p>Chairman of the Committee of Independent Directors</p> <p>(DIN 02410695)</p>

MUTUALFUNDS

Sahi Hai



UTI Mutual Fund

Haq, ek behtar zindagi ka.

Notice For Declaration Of

Income Distribution Cum Capital Withdrawal

UTI Conservative Hybrid Fund (Erstwhile UTI Regular Savings Fund)

Name of the Plan	Quantum of IDCW (Gross Distributable Amt.)*		Record Date	Face Value (per unit)	NAV as on July 28, 2025 (per unit)
	%	₹ per unit			
UTI Conservative Hybrid Fund - Regular Plan - Monthly Income Distribution cum capital Withdrawal option (IDCW)	0.80%	0.0800	Friday August 01, 2025	₹10.00	17.5887
UTI Conservative Hybrid Fund - Direct Plan - Monthly Income Distribution cum capital Withdrawal option (IDCW)					19.7978

*Distribution of above IDCW is subject to the availability of distributable surplus as on record date. Income distribution cum capital withdrawal payment to the investor will be lower to the extent of statutory levy (if applicable). Income distribution will be made, net of tax deducted at source as applicable.

Pursuant to payment of IDCW, the NAV of the income distribution cum capital withdrawal options of the scheme would fall to the extent of payout and statutory levy (if applicable).

Such of the unitholders under the income distribution cum capital withdrawal options whose names appear in the register of unitholders as at the close of business hours on the record date fixed for each income distribution cum capital withdrawal shall be entitled to receive the income distribution cum capital withdrawal so distributed. The reinvestment, if any, shall be treated as constructive payment of IDCW to the unitholders as also constructive receipt of payment of the amount by the unitholders. No load will be charged on units allotted on reinvestment of IDCW.

Mumbai

July 29, 2025

Toll Free No.: 1800 266 1230

www.utimf.com

REGISTERED OFFICE: UTI Tower, 'Gn' Block, Bandra Kurla Complex, Bandra (E), Mumbai - 400051. Phone: 022 - 66786666. UTI Asset Management Company Ltd. (Investment Manager for UTI Mutual Fund) E-mail: invest@uti.co.in, [CIN:L65991MH2002PLC137867].

For more information, please contact the nearest UTI Financial Centre or your AMFI/ NISM certified Mutual Fund Distributor, for a copy of Statement of Additional Information, Scheme Information Document and Key Information Memorandum cum Application Form.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

PHARMAIDS PHARMACEUTICALS LIMITED

Registered Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14, HMT Factory Main Road, Peenya Plantation, Bengaluru, Karnataka, India - 560013. | Corporate Identification Number: L52520KA1989PLC173979
Tel: +91-9611551732 / 080-49784319 | Email: compliance@pharmaids.com | Website: www.pharmaids.com

Recommendations of the Committee of Independent Directors (the “IDC”) of Pharmaids Pharmaceuticals Limited (the “Target Company”) under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (the “SEBI (SAST) Regulations, 2011”) in relation to the open offer to the public shareholders of the Target Company made by Shankarappa Nagaraja Vinaya Babu (“Acquirer”), along with Tumkur Trade Centre Private Limited (“PAC”).

Sr. No.	Topic	Particular
1.	Date	July 28, 2025
2.	Name of the Target Company	Pharmaids Pharmaceuticals Limited
3.	Details of the Offer pertaining to Target Company	The Open Offer is being made by the Acquirer along with PAC in terms of Regulations 3(1) and 4 of the SEBI (SAST) Regulations, 2011 for acquisition of up to 91,69,632 (Ninety One Lakh Sixty Nine Thousand Six Hundred Thirty Two) fully paid-up equity shares of face value of ₹10/- each (the “Equity Shares”), representing 26% (Twenty Six Percent) of the total Voting Share Capital of the Target Company on a fully diluted basis from the eligible shareholders of the Target Company for cash at a price of ₹ 62.15/- (Rupees Sixty Two Point One Five Only) per equity share (“Open Offer”).
4.	Name of the Acquirer and PAC with the Acquirer	Acquirer: Shankarappa Nagaraja Vinaya Babu PAC: Tumkur Trade Centre Private Limited CIN: U45403KA2018PTC113380
5.	Name of the Manager to the Offer	Saffron Capital Advisors Private Limited 605, Sixth Floor, Centre Point, Andheri-Kurla Road, J. B. Nagar, Andheri (East), Mumbai-400 059 Maharashtra, India. Tel. No.: +91 22 49730394 Email Id: openoffers@saffronadvisor.com Website: www.saffronadvisor.com Investor Grievance Id: investorgrievance@saffronadvisor.com SEBI Registration Number: INM000011211 Contact Person: Satej Darde / Sachin Prajapati
6.	Members of the Committee of Independent Directors (“IDC Members” or “Members of the IDC”)	i. Mr. Pattamadai Natarajasarma Vijay (DIN: 00049992) – Chairperson and Member ii. Mr. Methuku Nagesh (DIN: 01634324) - Member iii. Mr. Mopperthy Sudheer (DIN: 00404917) - Member
7.	IDC Member’s relationship with the Target Company (Director, Equity shares owned, any other contract / relationship), if any	i. All IDC Members are Independent and Non -Executive Directors on the Board of the Target Company. ii. Further, the members of IDC confirm that they do not hold any Equity Shares or other securities in the Target Company. iii. Other than their positions as Directors of the Target Company, there are no other contracts or relationships with the Target Company.
8.	Trading in the Equity shares/ other securities of the Target Company by IDC Members	None of the members of the IDC has traded in Equity Shares/ other securities of the Target Company during the: i. 12 (twelve) months period prior to the date of the Public Announcement (“PA”) dated Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.
9.	IDC Member’s relationship with the acquirer (Director, Equity shares owned, any other contract / relationship), if any.	None of the members of the IDC have any contractual or any other relationship with the Acquirer along with PAC.
10.	Trading in the Equity shares/ other securities of the Acquirer by IDC Members	Not Applicable as the Acquirer is an individual. Further, none of the IDC members has traded in Equity Shares of PAC during the: i. 12 (twelve) months period prior to the date of the PA i.e., Friday, December 27, 2024; and ii. period from the date of the PA till the date of this recommendation.
11.	Recommendation on the Open offer, as to whether the offer, is or is not, fair and reasonable	Based on the review, a) The IDC Members are of the view that the Offer Price of ₹62.15/- (Rupees Sixty Two Point One Five only) per Equity Share is in line with the parameters prescribed by the SEBI (SAST) Regulations, 2011; b) IDC Members believe that the Offer is in line with the SEBI (SAST) Regulations, 2011 and the same is fair and reasonable. However, IDC members would like to draw the attention of the Shareholders that, the Equity Shares of the Target Company are trading on BSE at a price that is higher than the Offer Price; and c) It is advised to the shareholders to independently evaluate the open offer vis-à-vis current share price and take an informed decision before participating in the Offer.
12.	Summary of reasons for recommendation	1. The IDC Members have reviewed: a) Public Announcement (“PA”) dated December 27, 2024; b) Detailed Public Statement (“DPS”) dated January 02, 2025 and was published on January 03, 2025; c) Draft Letter of Offer (“DLOF”) dated January 10, 2025; d) Letter of Offer (“LOF”) dated July 23, 2025; 2. The IDC members also noted that: a) The Equity Shares of the Target Company are frequently traded in terms of Regulations 2(1)(i) of the SEBI (SAST) Regulations, 2011. b) The Offer Price is in accordance with Regulations 8(1) and 8(2) of the SEBI (SAST) Regulations, 2011. c) The Offer Price of ₹ 62.15/- per Equity Share is higher than (i) negotiated price under the Share Purchase Agreement executed on December 27, 2024, i.e. ₹35/- per Equity Share and higher than (ii) the volume-weighted average market price of shares for a period of sixty trading days immediately preceding the date of the PA as traded on the BSE, being only stock exchange where the equity shares of the Target Company are listed, i.e. ₹62.13/- per Equity Share. Based on the above, the IDC Members are of the view that the Offer Price of ₹ 62.15/- per equity share is in line with the parameters prescribed by SEBI (SAST) Regulations, 2011.
13.	Disclosure of voting pattern	These recommendations were unanimously approved by the Members of the IDC.
14.	Details of Independent Advisors, if any.	None
15.	Any other matter to be highlighted	None

For and on behalf of the Committee of Independent Directors of Pharmaids Pharmaceuticals Limited

Sd/-

Pattamadai Natarajasarma Vijay

Chairperson of IDC

DIN: 00049992

Place: Philadelphia, Pennsylvania, USA

Date: July 28, 2025

AdBaz

Terms not defined herein carry the meaning ascribed to them in the Letter of Offer dated July 23, 2025.

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the SEBI (SAST) Regulations, 2011.

For and on behalf of the Committee of Independent Directors of Pharmaids Pharmaceuticals Limited

Sd/-

Pattamadai Natarajasarma Vijay

Chairperson of IDC

DIN: 00049992

PPFAS Mutual Fund

PPFAS Asset Management Private Limited
(Investment Manager to PPFAS Mutual Fund)
Registered Office: - 81/82, 8th Floor, Sakhar Bhavan, Ramnath Goenka Marg, 230 Nariman Point, Mumbai - 400 021, Maharashtra, INDIA.
Tel.: 91 22 6140 6555 Fax: 91 22 6140 6590. E-mail: mf@ppfas.com.
Website: www.amc.ppfas.com CIN No: - U65100MH2011PTC220623

NOTICE

Hosting of Annual Report and Abridged Annual Report of the Schemes of PPFAS Mutual Fund:

NOTICE is hereby given that in terms of Regulation 54 and 56 of Securities & Exchange Board of India (Mutual Funds) Regulations, 1996 read with SEBI Master Circular no. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27, 2024, the Scheme Annual Report and Abridged Annual Report (“the Annual Reports”) of PPFAS Mutual Fund for the period ended 31st March, 2025 have been hosted on the website of PPFAS Mutual Fund viz., www.amc.ppfas.com and on the website of Association of Mutual Funds in India, www.amfiindia.com. Investors can access / download the Reports from the above-mentioned websites.

Further, investors can submit a request for a physical or electronic copy of Scheme Annual Report or abridged summary thereof by any of the following modes at free of cost:

1. Email to us at mf@ppfas.com or
2. Contact us at Investor Helpline no. 1800-266-7790 or
3. Sending a written request at the Registered office address of the PPFAS AMC given above.

For PPFAS Asset Management Private Limited
(Investment Manager to PPFAS Mutual Fund)

Sd/-

Director

Place: Mumbai


Date: July 29, 2025

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

PPFAS

MUTUAL FUND

There's only one right way®



गृहम हाऊसिंग फायनान्स लिमिटेड

(पूर्वी पुढावाला हाऊसिंग फायनान्स लि. म्हणून ओळखले जाणारे)

नोंदणीकृत कार्यालय : द्वा मजला, बी बिल्डिंग, गंगा ट्रस्टो, लोहगाव, पुणे, महाराष्ट्र ४११०१४. शाखा कार्यालय दुनिट: शिवकला आर्कडॅड, ८ला मजला, शिवकला आर्कडॅड, तारारूप रोड, बोईसर, मुंबई, महाराष्ट्र-४०१५०१.

ई-लिलाव - विक्री सूचना

सरकेसी अधिनियम अंतर्गत ताराण स्थावर मत्तेची विक्री

सिक्कुरिटीझेशन अँड रिकन्स्ट्रक्शन ऑफ फायनान्सियल अँसेट अँड एनफोर्समेंट ऑफ सिक्कुरिटी इंटरॅस्ट अँसेट, २००२ (“कायदा”) सहवाचता सिक्कुरिटी इंटरॅस्ट (एनफोर्समेंट) रुस २००२ चा नियम ८ आणि ९ अंतर्गत स्थावर मालमत्तेची विक्रीकरीता विक्री सूचना. याद्वारे सर्वसामान्य जनतेला आणि विशेषतः कर्जदार/सह-कर्जदार/गहाणदार/हमीदारांना नोंटिस देण्यात आली आहे की, खाली वर्णन केलेल्या स्थावर मालमत्ता गृहम हाऊसिंग फायनान्स लिमिटेड (पूर्वी पुढावाला हाऊसिंग फायनान्स लिमिटेड) या नावाने ओळखले जाणारे, जे पुढावाला हाऊसिंग फायनान्स लिमिटेड हे नाव १७ नोव्हें. २०२३ च्या प्रभावापासून गृहम हाऊसिंग फायनान्स लिमिटेड असे बदलले गेले (पूर्वी सॅन्गा हाऊसिंग फायनान्स लिमिटेड म्हणून ओळखले जात होते आणि म्हणून: जॉर्जि मनी हाऊसिंग फायनान्स कंपनीच्या नावाने समविष्ट होते) (अधिनियमानुसार “ताराण धनको” म्हणून संबोधित), ज्याचा तावा ताराण धनको द्वारे प्राधिकृत अधिकाऱ्याने कायदाच्या कलम १३(१२) सहवाचता च्या नियम ८ आणि ९ सह वाचलेल्या अधिकाऱ्याचा वापर करून घेतला आहे. कायदाच्या कलम १३(१) सहवाचता सिक्कुरिटी इंटरॅस्ट (एनफोर्समेंट) रुस २००२ चा नियम ८ आणि ९, जे अधिनियमच्या कलम १३ (२) अंतर्गत सूचनेला अनुसरून आहे. ताराण मत्ता ई-लिलावाद्वारे “जसो आहे जेथे आहे” “जसो आहे की आहे”, आणि “जे काही तेथे आहे” या आधारार ३०/०८/२०२५ रोजीस विक्रीची जाईल. याद्वारे सर्वसामान्य जनतेला कळविण्यात येते की, आम्ही https://www.bankauctions.com या वेबसाईटवर प्रदान केलेल्या ई-लिलाव प्लॅटफॉर्मद्वारे सार्वजनिक करणार आहोत. विक्रीच्या तयारीलावर अटी आणि नियमांसाठी, कृपया जाईलपुष्कळ/ताराण धनकोच्या वेबसाईटवर दिलेल्या लिंकचा संदर्भ घ्या, म्हणजे www.grihumhousing.com परत.

अ. क्र.	प्रस्ताव क्र. ग्राहकाचे नाव (ए)	यागणी सूचना तारीख आणि धककाकोची रक्कम (सी)	तात्काचे स्वरूप (सी)	मालमत्तेचे वर्णन (डी)	राखीव रक्कम (ई)	इअर (आपरी च्या १००%) (एफ)	इअर सादरीकरण तारीख (जी)	बोली बाध रक्कम (एच)	मालमत्तेची तपसणी तारीख आणि वेळ (आय)	लिलावाची तारीख आणि वेळ (जे)	जात भार / न्यायालयाचीन प्रकाशने असण्यास (के)
१	कॉर्ज. क्र. एचएफ००१९६एच२११००१९१ पुवम मोविड पतनी (कर्जदार) २. कांको पुवम पतनी (सह कर्जदार)	सूचना तारीख: १०/०३/२०२५ एकुण धकीत: रु. ९९७२३६/- (रुपये नऊ लाख सव्याण्णव हजार दोनशे छत्तीस मात्र) १०/०३/२०२५ रोजीस एकत्रित सह परफेक्ठीयवत द.सा. १३.६०% दाने पुढील व्याज.	प्रत्यक्ष	गाव पासवत, ता. आणि बि. पालार येथे स्थित असलेले आणि वसलेले जमीन धारक सर्व्हे क्र. ७/२, ८/५ आणि १५/२, परिवार कॉम्प्लेक्सचा टाईन डी, इमारत क्र. ४, परिवार डी बिग नावे जात इमारत ३ रा मजलावर प्लॉट क्र. ३०७, क्षेत्र मोज. २३.८२ चौ.मीटर्सचे ते सर्व भाग आणि विभाग, प्लॉटच्या सीमाबद्ध: पूर्व: एनए, पश्चिम: एनए, उत्तर: एनए, दक्षिण: एनए.	रु. १११७२००/- (रुपये एक लाख अकरा हजार सातशे बीस मात्र)	१११७२०/-	२९/०८/२०२५	₹०,०००/-	२३/०८/२०२५ स. ११.०० ते दु. ४.००	३०/०८/२०२५ स. ११.०० ते दु. ४.००	गृह्य
२	कॉर्ज. क्र. एचएफ००१९६एच२११००५६८ जिनिटुसिंग खिमसिंग राजपुरोहित (कर्जदार) २. खिमसिंग कृष्णरावपुरोहित (सह-कर्जदार) ३. नैना राजपुरोहित (सह-कर्जदार)	सूचना तारीख: १०/०५/२०२५ एकुण धकीत: रु. ५०२२६७/- (रुपये पचास लाख वेचाळीस हजार नऊशे सारुद मात्र) १०/०५/२०२५ रोजीस एकत्रित सह परफेक्ठीयवत द.सा. १२.८५% दाने पुढील व्याज.	प्रत्यक्ष	गाव वळोबा, ता. पन्वेल, जिल्हा रायगड येथे स्थित असलेले आणि वसलेले धारक प्लॉट क्र. ४५, सेक्टर २ रा बांधलेले गिरमे कृपा रेसिडन्सी को अपार्टमेंट हाऊसिंग सोसायटी लि. नावे जात सोसायटी मध्ये की कृपा रेसिडन्सी नावे जात इमारतीमध्ये ४ रा मजलावर प्लॉट क्र. ४०१ जे सर्व ते परिसर. यानंतर संक्षिपणे सदर मिळकत असा संदर्भ. प्लॉटच्या सीमा: पूर्व: २० मीटर्स मोठा रोड, पश्चिम: प्लॉट क्र. ३३ आणि ३४, उत्तर: प्लॉट क्र. ४८, दक्षिण: १० मीटर्स मोठा रोड	रु. ३५६१६००/- (रुपये पन्नास लाख एकसह हजार सहाशे मात्र)	३५६१६०/-	२९/०८/२०२५	₹०,०००/-	२३/०८/२०२५ स. ११.०० ते दु. ४.००	३०/०८/२०२५ स. ११.०० ते दु. ४.००	गृह्य

इच्छुक बोलीदार/खरेदीदारंना सुरक्षित कर्जदार शाखेला आणि लिलावाच्या मालमत्तेला भेट देण्याचा सद्वा दिला जातो आणि बोली सादर करण्यापूर्वी त्यातील पैसा वयाची चौकशी करून अतिरिक्त शुल्क, बोझा आणि कोणत्याही नुतीच -पड्याचे धित तपसवये आणि त्याने/तिने/त्यानी समाधान करावे.


सर्व पैधानिक देय जसे की मालमत्ता कर, वीज/पाणी देय, आणि मालमत्ता संलग्न इतर कोणतीही देयके असल्यास, यशस्वी बोलीदाराने निव्विल केली पाहिजेत आणि भरली जातील. इच्छुक बोलीदारानी पोर्टलवर स्वतःची नोंदणी करणे आवश्यक आहे आणि लिलाव सेवा प्रदाय सी १ इंडिया प्रा. लि. कडून लॉगिन आयडी आणि पासवर्ड ओगट प्राप्त करणे आवश्यक आहे, जे ई-बिडिंगसाठी अनिवार्य आहे). पत्ता - प्लॉट क्र. - ६८ ३रा मजला गुहावा हरियाणा-१२२००३. हेल्पलाइन क्रमांक- ७९९९८११४४,२५,२६ सपोर्ट ईमेल आयडी - Support@bankauctions.com. संयोजक व्यक्ती - धर्मी श्री, ईमेल आयडी - dharani.p@ctiindia.com.संयोजक क्र- ९९४८८२२२२ कृपया लक्षात घ्या की, संभाव्य बोलीदार केवळ त्यांच्याकडूनच ई-लिलावावर ऑनलाईन प्रशिक्षण घेऊ शकतात. इच्छुक खरेदीदार/बिडाने अनैस्य मनी डिपॉझिट (इशे) परफेक्टी/आटीबीए/डीडी द्वारे पुढावाला हाऊसिंग फायनान्स लिमिटेड, बँक-आयसीआयसीआय बँक लि. च्या खात्यात जमा करणे आवश्यक आहे. खाते क्रमांक-०९५५५१००००२८ आणि आयएफएससी कोड- आयसीआयसीआय००००९१५, आयसीआयसीआय बँक लि., एचसील टेक पार्क, गणपती चौक जवळ, ४३/४४ विमान नगर-४११०१४ कोणत्याही दृष्टीकडून किंवा येडुबुल बँकवर २५/०८/२०२५ रोजी किंवा त्यापूर्वी काढलेले आणि त्यांचे नावे https://www.bankauctions.com वर नोंद घ्या आणि मिळवा. वापरकर्ता आयडी आणि पासवर्ड विनामूल्य आणि सेवा प्रदायाकडून ई-लिलावावर प्रशिक्षण घ्या. वेबसाईटवर नोंदणी केल्यानंतर, इच्छुक खरेदीदार/बिडाने खालील कागदपत्रांच्या प्रती अपलोड केल्या पाहिजेत. ई-मेस कार्यालय आणि ऑफिस क्रमांक ६०४, सहवा मजला, गौरी कॉम्प्लेक्स कॉम्प्लेक्स, प्लॉट क्रमांक १५, सेक्टर १५, सीबीडी बेलारूप, नवी मुंबई, ता. आणि जिल्हा. उणे-४००६१४ मोबाईल क्र. +९१ ९५६०२६२६०० ई-मेस आयडी rahul.r@grihumhousing.com. येथे स्व-साक्षात्कृत हार्ड कॉपी पाठवावी. ई-लिलावात भाग घेण्यासाठी अटी आणि शर्तीच्या अधिन राहिल्यात कृपया https://www.bankauctions.com आणि www.grihumhousing.com ला भेट द्या.

सदर नोंटिस सिक्कुरिटी इंटरॅस्ट (अंमलबजावणी) नियम, २००२ च्या नियम ८(६) अंतर्गत कर्जदार/सह-कर्जदार/गहाणदार/जमीनदाराना ३० दिवसांची नोंटिस म्हणून देखील विचारत घेतली जाईल.

कोणत्याही परिस्थितीत स्थानिक भाषेतील प्रकाशन आणि इंग्रजी वृत्तपत्र प्रकाशनातील मजकुरात काही फाट कर असल्यास, की प्रेस अंतर्लम्बचे प्रकाशित झालेल्या इंग्रजी वृत्तपत्र भाषेतील मजकुराला प्राधान्य दिले जाईल.

तारीख : ३०.०७.२०२५ ठिकाण : मुंबई

सही / - प्राधिकृत अधिकारी, गृहम हाऊसिंग फायनान्स लिमिटेड (पूर्वी पुढावाला हाऊसिंग फायनान्स लिमिटेड म्हणून ओळखले जाणारे)



INTERNATIONAL GEMMOLOGICAL INSTITUTE (INDIA) LIMITED

CIN: L46591MH1999PLC118476

Registered Office: 702, 7th Floor, The Capital, Bandra Kurla Complex, Bandra East, Mumbai - 400051, Maharashtra, India.

Email: investor.relations@igi.org | Website:www.igi.org

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED JUNE 30, 2025

(Amounts in INR millions, unless otherwise stated)

Particulars	Standalone					
	Quarter ended June 30, 2025 (Unaudited)	Corresponding quarter ended March 31, 2025 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Six months ended June 30, 2025 (Unaudited)	Six months ended June 30, 2024 (Unaudited)	Year ended December 31, 2024 (Audited)
Total income from operations	2,486.41	2,443.87	2,089.22	4,930.28	4,243.35	8,165.23
Net Profit for the period/ year (before tax)	1,807.88	1,876.36	1,314.73	3,684.24	2,996.96	5,868.27
Net Profit for the period/ year (after tax)	1,374.80	1,391.43	961.21	2,766.23	2,216.17	4,392.49
Total Comprehensive income for the period/ year (Comprising Profit/Loss) for the period (after tax) and Other comprehensive income (after tax)	1,371.46	1,388.03	961.21	2,759.49	2,203.03	4,378.89
Paid up Equity Share Capital (Face value of ₹ 2 per share)						864.32
Reserves excluding revaluation reserve as at Balance Sheet date						21,010.56
Earning per share:						
1. Basic (in ₹) (not annualised)	3.18	3.22	2.42	6.40	5.59	11.04
2. Diluted (in ₹) (not annualised)	3.06	3.09	2.42	6.15	5.59	10.57

(Amounts in INR millions, unless otherwise stated)


Particulars	Consolidate					
	Quarter ended June 30, 2025 (Unaudited)	Corresponding quarter ended March 31, 2025 (Unaudited)	Quarter ended June 30, 2024 (Unaudited)	Six months ended June 30, 2025 (Unaudited)	Six months ended June 30, 2024 (Unaudited)	Year ended December 31, 2024 (Audited)
Total income from operations	3,146.13	3,132.15	2,624.92	6,278.28	5,529.23	10,884.92
Net Profit for the period/ year (before tax)	1,749.69	1,914.73	1,139.96	3,660.42	2,850.85	5,853.20
Net Profit for the period/ year (after tax)	1,265.32	1,407.26	778.40	2,672.58	2,039.16	4,272.90
Total Comprehensive income for the period/ year (Comprising Profit/Loss) for the period (after tax) and Other comprehensive income (after tax)	1,341.76	1,451.88	716.32	2,793.64	1,963.63	4,336.18
Paid up Equity Share Capital (Face value of ₹ 2 per share)						864.32
Reserves excluding revaluation reserve as at Balance Sheet date						9,763.17
Earning per share:						
1. Basic (in ₹) (not annualised)	2.92	3.26	1.96	6.18	5.14	10.74
2. Diluted (in ₹) (not annualised)	2.81	3.13	1.96	5.94	5.14	10.28

Notes:

1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Reports) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on Stock Exchange websites.

2. The above financial results for the quarter ended June 30, 2025 have been duly reviewed by Audit Committee and were taken on record by the Board of Directors at its meeting held on July 29, 2025.

3. Figures for the previous periods have been regrouped/rearranged wherever necessary to confirm to current period's classification.



July 29, 2025
Mumbai

By order of the Board

Sd/-

Tehmasp Printer

(Managing Director & CEO)